Clinical trial · Observational
The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
Additional Blood Test Enhances Diagnostic Sensitivity of Relapse Detection and Predicts Survivals in High-risk Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An additional blood test at 2-3 months after RT is a valuable biomarker in predicting treatment outcome for NPC patients. Patients with persistently detectable EBV DNA during re-staging survey 2-3 months after RT should strengthen adjuvant therapy due to very high subsequent relapse rate and poor survivals.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- plasma EBV DNA detectable
- description
- the NPC patient received curative treatment and post-treatment plasma EBV DNA was detectable.
- label
- plasma EBV DNA undetectable
- description
- the NPC patient received curative treatment and post-treatment plasma EBV DNA was undetectable.
Primary outcomes (1)
- measure
- relapse-free survival (RFS)
- timeFrame
- 5 years
- description
- From the end of treatment to clinical or pathological proven disease relapse
Secondary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * histologically-proven nasopharyngeal carcinoma without distant metastasis (M0) at initial presentation * NPC patients who finished curative RT with or without chemotherapy Exclusion Criteria: * initial present M1 disease * Secondary primary cancer diagnosed within 5 years * performance status (WHO scale) less than 2
References
Publications (0)
Data not yet available